M&A Deal Summary

Lilly Acquires Ivy Animal Health

On May 25, 2007, Lilly acquired life science company Ivy Animal Health

Acquisition Highlights
  • This is Lilly’s 5th transaction in the Life Science sector.
  • This is Lilly’s 10th transaction in the United States.
  • This is Lilly’s 1st transaction in Kansas.

M&A Deal Summary
Date 2007-05-25
Target Ivy Animal Health
Sector Life Science
Buyer(s) Lilly
Deal Type Add-on Acquisition
Advisor(s) BMO Capital Markets (Financial)

Target

Ivy Animal Health

Overland Park, Kansas, United States
Ivy Animal Health, Inc., a privately held applied research and pharmaceutical product development company focused on the animal health industry.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lilly

Indianapolis, Indiana, United States
Category Company
Founded 1876
Sector Life Science
Employees43,000
Revenue 34.1B USD (2023)
DESCRIPTION
Entrance to Eli Lilly's campus in Indianapolis, Indiana.
Entrance to Eli Lilly's campus in Indianapolis, Indiana.

Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

DEAL STATS #
Overall 11 of 34
Sector (Life Science) 5 of 27
Type (Add-on Acquisition) 9 of 27
State (Kansas) 1 of 1
Country (United States) 10 of 29
Year (2007) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-03-05 Hypnion

Lexington, Massachusetts, United States

Hypnion is a biotech company that researches and develops sleep disorder therapies. The company was set up in 2000 by a number of authoritative names in the field of sleep disorder research. It owns the rights to SCORE- 2004™, a method for testing drugs used to treat sleep and waking disorders, which allows quick and accurate measurement of the impact of a particular drug on a broad range of sleep and waking parameters.

Buy $315M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-07-08 SGX Pharmaceuticals

San Diego, California, United States

SGX Pharmaceuticals, Inc., based in San Diego, California, is a biotechnology company focused on drug discovery and development in the area of oncology.

Buy $64M
Mergr

Product

Company

Legal